Why Understanding the Import Process in Full Matters

Importing medicinal products into the European Union is one of the most heavily regulated logistics operations in any industry. The combination of pharmaceutical GMP requirements, customs and border control obligations, marketing authorisation conditions, and national licensing requirements creates a multi-layered compliance environment where a failure at any single point can result in a batch being held at the border, rejected by the receiving importer’s quality system, or refused certification by the Qualified Person. For directors and supply chain managers responsible for maintaining reliable product flow into the EU, a thorough understanding of the end-to-end import process is not optional knowledge.

This article sets out the principal steps in the importation of a medicinal product from a third-country manufacturing site into the EU, the regulatory requirements that govern each step, and the most significant decision points and risks that arise across the process. It is written from an operational perspective and is intended to be useful both for organisations establishing an import programme for the first time and for those reviewing and strengthening an existing one.

Step One: Establishing the Legal Framework for Import

Marketing Authorisation and Product Eligibility

Before any batch can be imported, the product must have a valid marketing authorisation issued by the European Medicines Agency or by a competent authority in an EU member state through the national or mutual recognition procedure. The marketing authorisation specifies, among other things, the approved manufacturing sites, the approved specifications for the product and its components, and the testing requirements for batch release. Any importation of a product that does not have a valid marketing authorisation, or that is imported from a manufacturing site not approved in the marketing authorisation, constitutes a serious regulatory violation regardless of the product’s quality.

For products in clinical development rather than commercial supply, a Clinical Trial Authorisation provides the equivalent framework, with different and in some respects more complex requirements for the management of investigational medicinal products. The import of IMPs involves additional considerations around blinding, randomisation, and the management of comparator products that do not apply to commercial supply.

Manufacturer’s and Importer’s Authorisation

The EU entity receiving the imported product must hold a Manufacturer’s Authorisation that covers the importation activity. This authorisation, issued by the competent authority in the relevant member state, confirms that the site meets the requirements of EU GMP and has in place a named Qualified Person responsible for batch certification. Operating as an importer of medicinal products without the requisite authorisation is a criminal offence in all EU member states.

The authorisation also specifies which products and which manufacturing operations the site is authorised to undertake, including whether it is authorised to conduct batch testing or whether it relies on contracted testing at another authorised site. Companies establishing an import operation for the first time should allow significant lead time for the authorisation application process, which in most member states involves a site inspection and cannot be expedited by commercial urgency.

Step Two: Qualifying the Third-Country Manufacturing Site

The EU importer is responsible for confirming that the third-country manufacturing site operates to GMP standards at least equivalent to those required in the EU. This confirmation must be based on adequate due diligence, which in practice means one or more of the following: a recent inspection of the site by a competent authority whose standards are recognised by the EU, a satisfactory audit conducted by or on behalf of the importer, or a well-established supply history with consistent quality performance and no significant regulatory findings.

The Written Confirmation requirement, introduced following amendments to Directive 2001/83/EC, requires that the competent authority of the exporting country provides formal written confirmation that the manufacturing site operates to GMP standards equivalent to those in the EU. This requirement applies to active pharmaceutical ingredient manufacturers supplying EU-marketed products and has added a layer of formality to the site qualification process that importers must manage proactively.

For sites covered by a Mutual Recognition Agreement between the EU and the relevant third country, the inspection record of the partner country’s regulatory authority may satisfy the GMP equivalence requirement, potentially reducing the need for EU-sponsored site audits. The QP must nonetheless maintain sufficient knowledge of the site’s compliance status to support their certification decisions, which means that MRA coverage does not eliminate the need for ongoing site quality oversight.

Step Three: Establishing Testing Arrangements

Each batch of imported medicinal product must undergo full analytical testing at a site holding a relevant Manufacturer’s Authorisation within the EU, unless a waiver applies under a Mutual Recognition Agreement. This testing covers the finished product specifications set out in the marketing authorisation, including identity, assay, purity, dissolution, microbiological testing where required, and any additional parameters specified in the product dossier.

The testing laboratory must be qualified by the importer, with an appropriate Quality Technical Agreement in place that defines the respective responsibilities of the importer and the laboratory, the testing protocols to be followed, the timelines for reporting results, the procedure for handling out-of-specification results, and the documentation requirements for the laboratory’s contribution to the batch release dossier. A laboratory that provides results without the supporting documentation required for QP review, or that fails to follow the testing protocols specified in the marketing authorisation, generates results that may not be acceptable for batch release regardless of the numerical outcome.

Step Four: Assembling the Batch Release Dossier

The batch release dossier is the compilation of documentation that the Qualified Person reviews before certifying a batch. Its composition is determined by the product’s marketing authorisation, the site’s Manufacturer’s Authorisation, and the applicable GMP guidelines, but typically includes the batch manufacturing records from the third-country site, the certificates of analysis from all testing conducted both at the manufacturing site and at the EU testing laboratory, environmental monitoring data for relevant manufacturing areas, any deviation reports and associated corrective actions arising during manufacture or testing, the Qualified Person release documentation from the manufacturing site, and any applicable customs or import documentation.

The quality and completeness of the batch release dossier is one of the most operationally significant variables in the efficiency of the import process. Dossiers that arrive incomplete, with missing documents, with untranslated records from non-English speaking manufacturing sites, or with deviations that have not been adequately documented and closed, delay the QP review and extend the time from batch arrival to market release. The importer’s quality management system should include processes for pre-screening the dossier before it is presented to the QP, identifying and resolving documentation gaps without requiring the QP’s time for routine chase-up activities.

Step Five: QP Certification and Batch Release

Following satisfactory review of the batch release dossier and confirmation that all analytical testing meets specification, the Qualified Person certifies the batch. This certification is recorded in a register that must be maintained at the import site and made available to the competent authority on request. The register provides a permanent record of every batch certified by the QP, the date of certification, and the basis on which the certification was made.

Once certified, the batch can be transferred to the distribution network and supplied to customers or healthcare providers in accordance with the distribution authorisation. The certified batch record must accompany the product through the supply chain and must be available for inspection by competent authorities at any point. For serialised products, the activation of the product’s unique identifier in the European Medicines Verification System marks the point at which the product is formally entered into the EU market supply chain.

For companies managing complex import programmes across multiple products and manufacturing sites, having access to experienced EU import and batch release expertise ensures that each step in the process is managed to the standard that regulators and customers expect. Inglasia’s specialist EU import and batch release services support organisations across the full import workflow, from site qualification through to QP certification and regulatory reporting.

Step Six: Post-Release Obligations

Batch release is not the end of the importer’s obligations. The importer retains responsibility for the product throughout its time on the EU market, including obligations related to pharmacovigilance reporting, product recall management, variations to the marketing authorisation that affect already-released batches, and the maintenance of reference and retention samples at the import site. The retention sample requirement, which mandates that a sample of each certified batch be retained at the EU import site for a defined period, provides the mechanism for re-testing in the event of a quality complaint or post-market safety concern.

Importers must also maintain their quality management systems in a state of ongoing readiness for inspection by the competent authority. Unannounced inspections are conducted in all EU member states, and an import operation that is inspection-ready only when advance notice has been given is an operation carrying significant regulatory risk. The documentation, the trained personnel, the validated processes, and the functioning quality systems must be in place and demonstrably operational at all times.

Conclusion

The importation of medicinal products into the EU is a structured process governed by a complex and interconnected set of regulatory requirements, each of which must be met before a batch can legitimately reach patients. Organisations that understand this process in full, and that have built the infrastructure to manage it reliably at scale, are those best positioned to maintain product availability without the regulatory disruption that compliance failures create. To discuss how your organisation can strengthen its EU import process, get in touch with our team.